Comment on: "A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis"

Pharmacoeconomics. 2018 Jul;36(7):879. doi: 10.1007/s40273-018-0655-0.

Author

Ena Singh¹

Affiliation

¹ Gastroenterology, Inflammation and Immunology, Medical Affairs, Pfizer Inc, 500 Arcola Rd, Collegeville, PA, 19426, USA. Ena.Singh@pfizer.com.

PMID: 29725873
DOI: 10.1007/s40273-018-0655-0

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biological Factors
Biological Products*
Colitis, Ulcerative*
Cost-Benefit Analysis
Humans
Infliximab

Substances

Biological Factors
Biological Products
Infliximab